Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive’s Tylah Tully to discuss the latest milestone of being granted an Australian patent for its synthetic anti-infectives, solidifying global patent protection for its key assets.
The Patent Family 3 approval by the Australian Patent Office extends coverage of RECCE® 327 (R327) and RECCE® 529 (R529) until 2037.
This completes Recce’s intellectual property protection in major markets, including the US, Europe, China, Japan and others.
The patent encompasses the manufacturing process for RECCE® anti-infectives, their use in treating infections and methods of administration, including oral, injectable, inhalable and transdermal applications.
Graham noted that the milestone bolstered Recce’s global position in addressing critical viral and bacterial threats with innovative therapies.
The company’s pipeline focuses on tackling antibiotic-resistant superbugs, with R327 and R435 targeting bacterial infections and R529 aimed at viral infections.
Recognised by the WHO for its innovative approach, Recce has also received FDA designations for R327, providing 10 years of market exclusivity upon approval.
The company’s proprietary manufacturing capabilities support its clinical trials as it advances solutions for unmet medical needs.